What is Tianjin Pharmaceutical Da Ren Tang Group Net Current Asset Value?
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
SHSE:600329'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.51 Med: 6.5 Max: 21.51
Current: 8.45
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Tianjin Pharmaceutical Da Ren Tang Group was 21.51. The lowest was 3.51. And the median was 6.50.
SHSE:600329's Price-to-Net-Current-Asset-Value is ranked worse than 65.61% of 602
companies
in the Drug Manufacturers industry
Industry Median: 5.62
vs SHSE:600329: 8.45
Tianjin Pharmaceutical Da Ren Tang Group Net Current Asset Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Tianjin Pharmaceutical Da Ren Tang Group Net Current Asset Value Chart
Tianjin Pharmaceutical Da Ren Tang Group Annual Data
Competitive Comparison of Tianjin Pharmaceutical Da Ren Tang Group's Net Current Asset Value
For the Drug Manufacturers - Specialty & Generic subindustry, Tianjin Pharmaceutical Da Ren Tang Group's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tianjin Pharmaceutical Da Ren Tang Group's Price-to-Net-Current-Asset-Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tianjin Pharmaceutical Da Ren Tang Group's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Tianjin Pharmaceutical Da Ren Tang Group's Price-to-Net-Current-Asset-Value falls into.
Tianjin Pharmaceutical Da Ren Tang Group Net Current Asset Value Calculation
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Tianjin Pharmaceutical Da Ren Tang Group Net Current Asset Value Related Terms
Thank you for viewing the detailed overview of Tianjin Pharmaceutical Da Ren Tang Group's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Business Description
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company manufactures and sells traditional Chinese medicine, western medicine, and healthcare products in the People's Republic of China. It operates in two segments namely The Chinese Medicine segment and The Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese pharmaceutical products.
Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SHSE:600329 has been successfully added to your 